about
Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malariaChlorproguanil-dapsone for treating uncomplicated malariaSulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malariaChlorproguanil-dapsone for treating uncomplicated malariaMolecular characterisation of drug-resistant Plasmodium falciparum from ThailandA randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.Population genetic analysis of Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assayEfficacy of Chloroquine for the Treatment of Vivax malaria in Northwest EthiopiaTargeting purine and pyrimidine metabolism in human apicomplexan parasitesGlobal change and human vulnerability to vector-borne diseasesThe chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferencesWISDOM-II: screening against multiple targets implicated in malaria using computational grid infrastructures.Comparative transcriptional and genomic analysis of Plasmodium falciparum field isolates.Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparumNew class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsinsAntimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.Acridine Orange for malaria diagnosis: its diagnostic performance, its promotion and implementation in Tanzania, and the implications for malaria control.Population, behavioural and environmental drivers of malaria prevalence in the Democratic Republic of Congo.Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenaseThe implementation of a new Malaria Treatment Protocol in Timor-Leste: challenges and constraints.Recent advances in antimalarial drug development.Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug developmentChanging the malaria treatment protocol policy in Timor-Leste: an examination of context, process, and actors' involvementTriazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.Prevalence of drug resistance associated mutations in Plasmodium vivax against sulphadoxine-pyrimethamine in southern PakistanDoes the drug sensitivity of malaria parasites depend on their virulence?Drug resistance and genetic mapping in Plasmodium falciparum.In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1.Synthesis, biological evaluation and structure-activity relationships of new quinoxaline derivatives as anti-Plasmodium falciparum agents.A plastid segregation defect in the protozoan parasite Toxoplasma gondii.In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation.Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum.Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors.Chloroquine is not a risk factor for seizures in childhood cerebral malaria.Novel oxazine skeletons as potential antiplasmodial active ingredients: Synthesis, in vitro and in vivo biology of some oxazine entities produced via cyclization of novel chalcone intermediates.Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.Reversed chloroquines based on the 3,4-dihydropyrimidin-2(1H)-one scaffold: synthesis and evaluation for antimalarial, beta-haematin inhibition, and cytotoxic activity.Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
P2860
Q24244592-B72CB398-9E85-4C06-910D-E1B60CCFFDC9Q24245853-7B68DBD4-0E23-49F4-AEB3-AD7D07F571B4Q24246263-68C3BD0F-9BA6-41B3-B1C4-BD39525FC3AAQ24248110-26D15BDC-1A94-4096-943C-370D74801730Q24799200-0EE88A10-746A-46C8-B3CC-39E42FBC6BFDQ24814579-A75CFDB7-6521-43A6-82AF-DD74C6D6B9CDQ28478444-44FCB72B-1F02-446D-BB47-4D80C95C36E9Q28553811-C57FBA28-984F-4D86-B478-DE921381E0F9Q28629739-EC931589-00CF-473D-BC01-4469044555F8Q28776363-4183E8ED-B363-4181-AC91-55BE9E0772C6Q30041470-2F1EF69E-6F42-431F-81FB-97E4628F8B08Q33437882-F5ECC86F-C136-4CD0-B258-0C5BD749A601Q33515574-A4630A68-7FE1-4719-88A7-A62A4F266E06Q33981743-2577FF52-03F9-451D-9499-EFADDF0DE069Q33982942-5D9E2D91-CC81-4E50-BD16-BD6AD2636FCDQ34228300-1073EE5D-36A5-4623-A30F-6240CCFFDC56Q35049324-9D646927-ED5D-495B-92BB-5FD794A1CE89Q35136234-245F8868-F722-4DDF-85B7-A70CB24704F0Q36235143-D748E545-AF7E-4E03-8213-F0ECE9B93A39Q36247004-AAF6FF46-D742-4462-BC63-65D19DD81E2EQ36443296-5D4EA962-0507-4353-9615-88B7BF3D925BQ36478346-A209EDAF-0C0C-46F3-ACAB-07D10ECFA516Q36643383-9C8CCA12-780D-47BE-9F45-CD0466062F84Q36880704-47FF9C2E-D4FC-4582-844F-2814D34C7538Q37057973-AEE72399-A3EF-4C51-A9DE-1CC6C8784B78Q37070636-029CD5A3-A7C4-43FE-97DF-A39B828D7E00Q37085908-7C25E55A-44FB-4921-8268-433C37EF8730Q37273348-9FEABB9E-0EAA-44AC-AFB6-A6E86F57E745Q37392627-4E2860E8-712C-434E-9EAB-4105177CEB3DQ39022462-7C63DD08-DE37-4B37-A1E9-137913E8329FQ39673553-D882E897-2085-4F98-B286-65380A70C5B2Q40059572-693CC445-A6B7-4789-941F-46E1B71DF803Q41745894-F947A24F-FD42-481C-A7CC-18DBAC1AB4F1Q41916277-D02DC0B1-A548-4218-8582-A6D8881C5365Q41920435-5C9EC239-50CC-4114-9067-360CB48C1464Q41934129-C3400149-4AD5-47B8-8F27-9F85D7707969Q41937177-1867125E-738F-49B3-8B79-CEA544652DEAQ41940021-29095CB0-D7A6-4DE4-903C-3C48D5FA67DDQ42808168-79711ABD-9BA4-45BA-B5BB-C99F9341D58AQ44110006-A1ADF17E-7913-402B-AB14-72D1E08BA247
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Drug resistance in malaria.
@ast
Drug resistance in malaria.
@en
type
label
Drug resistance in malaria.
@ast
Drug resistance in malaria.
@en
prefLabel
Drug resistance in malaria.
@ast
Drug resistance in malaria.
@en
P1476
Drug resistance in malaria.
@en
P304
P356
10.1093/OXFORDJOURNALS.BMB.A011721
P577
1998-01-01T00:00:00Z